Endogenous opioid signalling regulates spinal ependymal cell proliferation

Wendy W S Yue1, Kouki K Touhara2, Kenichi Toma3

  • 1Department of Physiology, University of California, San Francisco, CA, USA. wingszewendy.yue@ucsf.edu.

Nature
|September 18, 2024
PubMed

Insights

Researchers discovered a new signaling pathway involving kappa-opioids that controls ependymal cell proliferation after spinal cord injury. This finding offers a potential strategy for modulating scar formation and improving neural regeneration.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Regenerative Medicine

Background:

  • Spinal cord injuries lead to scarring, which can impede neural regeneration and functional recovery.
  • While astrocytes are known scar-forming cells, ependymal cells also contribute significantly to scar tissue after injury.
  • The mechanisms controlling ependymal cell proliferation post-injury are not well understood.

Purpose of the Study:

  • To identify endogenous mechanisms regulating ependymal cell proliferation following spinal cord injury.
  • To explore the role of kappa-opioid signaling in controlling ependymal cell behavior.
  • To investigate potential therapeutic targets for modulating spinal cord scarring.

Main Methods:

  • Investigated the expression of kappa-opioid receptor (OPRK1) in cerebrospinal fluid-contacting neurons (CSF-cNs).
  • Identified prodynorphin (PDYN) expression in cells neighboring CSF-cNs.
  • Utilized kappa-opioid antagonists and agonists to assess effects on ependymal proliferation in vitro and in vivo, including after injury models.

Main Results:

  • Kappa-opioid signaling, mediated by OPRK1 in CSF-cNs, inhibits ependymal cell proliferation.
  • PDYN-expressing cells release kappa-opioids that stimulate CSF-cNs, suppressing ependymal proliferation.
  • Systemic kappa-antagonist administration increased ependymal proliferation, while a kappa-agonist reduced proliferation and scar formation post-injury, improving motor function.

Conclusions:

  • An endogenous kappa-opioid signaling pathway involving CSF-cNs and PDYN-expressing cells regulates ependymal proliferation.
  • This pathway represents a novel mechanism for controlling scar formation after spinal cord injury.
  • Targeting this pathway offers a potential pharmacological strategy to enhance neural regeneration and functional recovery.

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
584
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.2K
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
551